Bronfman E.L. Rothschild L.P. lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 19.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,147 shares of the biotechnology company’s stock after acquiring an additional 1,164 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in BioMarin Pharmaceutical were worth $673,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of BMRN. Thrivent Financial for Lutherans increased its stake in shares of BioMarin Pharmaceutical by 581.0% during the first quarter. Thrivent Financial for Lutherans now owns 1,224,776 shares of the biotechnology company’s stock valued at $99,293,000 after acquiring an additional 1,044,921 shares during the period. Frontier Capital Management Co. LLC grew its position in BioMarin Pharmaceutical by 42.8% in the second quarter. Frontier Capital Management Co. LLC now owns 1,210,472 shares of the biotechnology company’s stock worth $114,026,000 after buying an additional 362,531 shares during the last quarter. USS Investment Management Ltd grew its position in BioMarin Pharmaceutical by 22.9% in the first quarter. USS Investment Management Ltd now owns 1,339,671 shares of the biotechnology company’s stock worth $111,869,000 after buying an additional 249,738 shares during the last quarter. Canada Pension Plan Investment Board grew its position in BioMarin Pharmaceutical by 68.4% in the second quarter. Canada Pension Plan Investment Board now owns 427,999 shares of the biotechnology company’s stock worth $40,318,000 after buying an additional 173,850 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its position in BioMarin Pharmaceutical by 187.8% in the first quarter. State of Wisconsin Investment Board now owns 263,571 shares of the biotechnology company’s stock worth $21,368,000 after buying an additional 171,994 shares during the last quarter.

Several research analysts have issued reports on the stock. Credit Suisse Group lifted their price target on shares of BioMarin Pharmaceutical from $120.00 to $122.00 and gave the stock an “outperform” rating in a research report on Monday, July 9th. BidaskClub lowered shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. ValuEngine lowered shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. Stifel Nicolaus lifted their price target on shares of BioMarin Pharmaceutical from $102.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. Finally, Sanford C. Bernstein decreased their price target on shares of BioMarin Pharmaceutical from $97.00 to $92.00 and set a “market perform” rating on the stock in a research report on Monday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $116.28.

In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, July 23rd. The shares were sold at an average price of $101.69, for a total transaction of $152,535.00. Following the transaction, the chief executive officer now directly owns 286,790 shares in the company, valued at approximately $29,163,675.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Brian Mueller sold 2,021 shares of BioMarin Pharmaceutical stock in a transaction on Friday, June 15th. The shares were sold at an average price of $94.50, for a total transaction of $190,984.50. Following the sale, the senior vice president now directly owns 13,029 shares of the company’s stock, valued at approximately $1,231,240.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,874 shares of company stock worth $6,259,566. Corporate insiders own 1.90% of the company’s stock.

NASDAQ BMRN opened at $99.03 on Tuesday. BioMarin Pharmaceutical Inc. has a twelve month low of $75.81 and a twelve month high of $106.20. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.24 and a current ratio of 2.83.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The firm had revenue of $372.80 million for the quarter, compared to analysts’ expectations of $359.25 million. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. The company’s revenue for the quarter was up 17.4% on a year-over-year basis. equities analysts forecast that BioMarin Pharmaceutical Inc. will post -0.24 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Further Reading: Investing in Growth Stocks

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.